TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Transversus Abdominis Plane Block With Compound Lidocaine on Pain After Gynecological Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject is scheduled to undergo gynecological laparotomy under general anesthesia~2. Subject's American Society of Anesthesiologists physical status is I-II.~3. The subject's parent/legally authorized guardian has given written informed consent to participate.~Exclusion Criteria:~1. Subject has a diagnosis of bronchial asthma, coronary heart disease, severe hypertension, renal failure or liver failure.~2. Subject has a diagnosis of Insulin dependent diabetes.~3. Subject is allergy and contraindication to local anesthetics or any components of local anesthetics.~4. Subject has a history of chronic pain, a history of alcohol or opioid abuse, pre- existing therapy with opioids, intake of any analgesic drug within 48 hours before surgery.~5. Subject has any contraindication for the use of patient-controlled analgesia (PCA).~6. Subject is pregnant or breast-feeding.~7. Subject is obese (body mass index \>30kg/m\^2).~8. Subject is incapacity to comprehend pain assessment and cognitive assessment.

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Normal saline in transversus abdominis plane block (Type: PLACEBO_COMPARATOR): Before the induction of anesthesia, normal saline is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
- Ropivacaine in transversus abdominis plane block (Type: ACTIVE_COMPARATOR): Before the induction of anesthesia, 0.375% ropivacaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
- Compound lidocaine at low-concentration in transversus abdominis plane block (Type: ACTIVE_COMPARATOR): Before the induction of anesthesia, 0.4% compound lidocaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
- Compound lidocaine at high-concentration in transversus abdominis plane block (Type: ACTIVE_COMPARATOR): Before the induction of anesthesia, 0.6% compound lidocaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Controlled Trial of Erenumab in Migraine Prevention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has provided informed consent/assent prior to initiation of any study specific activities/procedures.~* Japanese subjects greater than or equal to 20 to less than or equal to 65 years of age upon entry into screening.~* History of migraine (with or without aura) for greater than or equal to 12 months before screening according to the International Headache Society Classification ICHD-3 (Headache Classification Committee of the International Headache Society, 2018) based on medical records and/or patient self-report~* Migraine frequency: Chronic Migraine (CM) or Episodic Migraine (EM) over the 3 months before screening based on the following criteria:~  1. CM is defined as greater than or equal to 15 headache days per month of which greater than or equal to 8 headache days on average across the 3 months meet criteria as migraine days~ 2. EM is defined as less than 15 headache days per month of which at least 4 or more headache days on average across the 3 months meet criteria as migraine days~Exclusion Criteria:~* Subjects greater than 50 years of age at migraine onset.~* History of cluster headache or hemiplegic migraine headache.~* Unable to differentiate migraine from other headaches.~* Migraine with continuous pain, in which the subject does not experience any pain-free periods (of any duration) during the 1 month before the screening period.~* Malignancy, except non-melanoma skin cancers, cervical or breast ductal carcinoma in situ within the last 5 years.~Other exclusion criteria may apply

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Erenumab (Type: EXPERIMENTAL): Participants were to receive erenumab 70 mg once a month for 24 weeks during the double-blind treatment period followed by erenumab 70 mg once a month for 28 weeks during the open-label treatment period.
- Placebo (Type: PLACEBO_COMPARATOR): Participants were to receive placebo to erenumab once a month for 24 weeks during the double-blind treatment period followed by erenumab 70 mg once a month for 28 weeks during the open-label treatment period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* All patients must have a histologic diagnosis of non-Hodgkin's lymphoma by brain biopsy. Patients who have an inconclusive biopsy or who are not candidates for biopsy may be eligible provided they have a typical cranial magnetic resonance imaging (MRI) or computed tomography (CT) scan and meet at least one of the following two criteria:~  * A positive cerebrospinal fluid (CSF) cytology for lymphoma or a monoclonal lymphocyte population as defined by cell surface markers~ * A biopsy of the vitreous or uvea demonstrating non-Hodgkin's lymphoma~* A typical MRI/CT scan for primary intracranial lymphoma is defined as the presence of hypo, iso, or hyperdense parenchymal contrast-enhancing (usually homogeneously) mass lesion(s)~* Patients must be HIV-1 negative~* Patients must have a normal or negative pre-treatment systemic evaluation including:~  * A bone marrow aspirate and biopsy~ * CT scans of the chest, abdomen and pelvis~ * Patients must have adequate bone marrow function (defined as peripheral leucocyte count \> 4000 cells/mm3 and platelet count \> 100,000 cells/mm3), liver function (bilirubin \< 2.0 mg and SGOT \< 2 times upper limit of normal), and adequate renal function (serum creatinine \< 1.5 mg/dl or creatinine clearance \> 50 cc/min/1.73M2)~* Men and women of reproductive potential must agree to use an acceptable method of birth control during treatment and for six months after completion of treatment~Exclusion Criteria:~The following would exclude a patient from the study:~* Prior cranial irradiation~* Other active primary malignancy with the exception of basal cell carcinoma of the skin and cervical carcinoma in situ~* Pre-existing immunodeficiency such as renal transplant recipient~* Prior treatment with chemotherapy for CNS lymphoma

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Weight of at least 88 pounds(40 kilograms)~* Diagnosis of Wegener's granulomatosis or microscopic polyangiitis according to the definitions of the Chapel Hill Consensus Conference~* Newly diagnosed patient of Wegener's granulomatosis or microscopic polyangiitis OR must be experiencing a disease flare characterized by: (a) active disease with a Birmingham Vasculitis Activity Score for Wegener's granulomatosis (BVAS/WG) of 3 or greater that would normally require treatment with CYC; OR (b) disease severe enough to require treatment with CYC; OR (c) must be positive for either PR3-ANCA (ANCA directed against proteinase 3) or MPO-ANCA (ANCA directed against myeloperoxidase)at the screening~* Willing to use acceptable forms of contraception for the duration of the study and for up to 1 year after stopping study medications~* Willing to report pregnancies (female participants or male participants' partners) occurring at any time during the study and for up to 1 year after stopping study medications~* Parent or guardian willing to provide informed consent, if applicable~Exclusion Criteria:~* Diagnosis of Churg-Strauss Syndrome according to the definitions of the Chapel Hill Consensus Conference~* Have limited disease that would not normally be treated with CYC~* Requires mechanical ventilation because of alveolar hemorrhage~* History of severe allergic reactions to human or chimeric monoclonal antibodies~* Active systemic infection~* Have a deep-space infection, such as osteomyelitis, septic arthritis, or pneumonia complicated by pleural cavity or lung abscess, within 6 months prior to study entry~* History of or current hepatitis B or C infection~* HIV (human immunodeficiency virus) infected~* Acute or chronic liver disease that, in the opinion of the investigator, may interfere with the study~* History of or active cancer diagnosed within the last 5 years. Individuals with squamous cell or basal cell carcinomas of the skin and individuals with cervical carcinoma in situ who have received curative surgical treatment may be eligible for this study.~* History of anti-glomerular basement membrane (anti-GBM) disease~* Other uncontrolled disease, including drug and alcohol abuse, that may interfere with the study~* Pregnancy or breastfeeding

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rituximab (Type: EXPERIMENTAL): None
- Control Group (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Intervention to Improve Coping With Discrimination and Adherence Among HIV-Positive Latino MSM

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years-old or older, HIV-positive, biologically male at birth and continue to identify as male, identify as Latino, report having sex with men in the past 12 months, and prescribed ART.~Exclusion Criteria:~* Being unwilling or unable to provide informed consent; having mental health problems that require immediate treatment (e.g., psychotic symptoms) or a diagnosed mental disorder that would limit ability to participate (e.g., dementia); and cognitive impairments that result in limited ability to provide informed consent.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Siempre Seguiré (Type: EXPERIMENTAL): We will conduct a small randomized controlled trial (RCT), testing study protocols and materials, the acceptability of randomization, and overall program feasibility. The pilot will help to identify logistical considerations; assess whether the program is acceptable and understandable LMSM; and collect initial data on how successfully the program motivates change in coping and adherence. It will allow us to estimate expected attrition and response rates, and to perform preliminary power analyses in preparation for a fully powered RCT.
- Control (Type: NO_INTERVENTION): Control participants will not be randomized to receive the intervention and will receive standard of care during the intervention period. We will offer the program to any interested control participants shortly after the 6-month follow-up surveys are completed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing Etanercept (ETN) Against a Placebo for Etanercept on a Background Nonsteroidal Anti Inflammatory Drug (NSAIDs) in the Treatment of Early Spondyloarthritis (SpA) Patients Who do Not Have X-ray Structural Changes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of axial spondyloarthritis as defined by Assessments in Ankylosing Spondylitis (ASAS)criteria~* Active symptoms defined as Ankylosing Spondylitis Disease Activity Index{BASDAI) \> or = 4~* Axial symptoms of back pain with a less than favorable response to on steroidal anti inflammatory drugs at optimal dosage for greater than 4 weeks~Exclusion Criteria:~* Evidence of current or recent episode of uveitis~* Evidence of IBD flare within 6 months~* Previous treatment with an anti Tumor necrosis factor(TNF)~* Active tuberculosis~* Radiographic sacroiliitis grade 3-4 unilaterally or \>= 2 bilaterally

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 49 Years
- Healthy Volunteers: f

Study Arms:
- etanercept (Type: ACTIVE_COMPARATOR): In Period 1 : Subjects will receive via a prefilled syringe an active dose equivalent to 1.0ml of Etanercept solution once weekly SC once weekly. Additionally they will continue to take the background non steroidal anti inflammatory drug(NSAID) in the tolerated dose agreed upon by the attending Physician.
- PLACEBO (Type: PLACEBO_COMPARATOR): In Period 1: Subjects will receive in a prefilled syringe with a PLACEBO dose equivalent to 1.0 ml of placebo solution once weekly SC Additionally they will continue to take the background non steroidal anti inflammatory drug(NSAID) in the tolerated dose agreed upon by the attending Physician.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pepsin in Patients With Functional Dyspepsia

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with dyspepsia~* Women and men aged between 18 and 75~Exclusion Criteria:~- Unwilling to consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Effects of Ganshuang Combined TDF to Treat CHB and NAFLD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Chronic hepatitis B patients not treated with antiviral drugs； Fatty liver was diagnosed by B-ultrasound and imaging； No history of excessive drinking； Good drug compliance and regular medication； Exclusion Criteria： Non chronic hepatitis B patients； Taking other drugs； liver failure, liver cancer and other diseases； patients who refused to sign informed consent；

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- The control group (Type: EXPERIMENTAL): The control group was treated with silibinin meglumine tablets and tenofovir
- The treatment group (Type: ACTIVE_COMPARATOR): The treatment group was treated with Ganshuang granules combined with silibinin meglumine tablets and tenofovir

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Pharmacotherapy of Psychotic Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Major depressive disorder, single or recurrent, with psychotic features~Exclusion Criteria:~* History of substance abuse or dependence within the 3 months prior to enrollment~* Acute or unstable medical illness~* Diagnosis of schizophrenia or other psychotic disorders~* Pregnant~* Intolerance to SSRIs or olanzapine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- olanzapine/sertraline combination (Type: ACTIVE_COMPARATOR): sertraline plus olanzapine
- olanzapine plus placebo (Type: PLACEBO_COMPARATOR): olanzapine (5 - 20mg/day) plus placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Unfavorable Bleeding Patterns in Contraceptive Implant Users

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* English or Spanish speaking~* women aged 15-45 years of age~* Currently using the ENG-implant for at least 1 month and use proven on exam (palpation of implant at screening visit)~* Willing to continue using the implant for at least 6 months~* \>7 days of continuous bleeding/spotting, or 2 or more episodes of bleeding/spotting in the last 30 days.~* Cellphone that is able to receive and respond to a daily text or email message .~Exclusion Criteria:~* Postpartum within six months~* post-abortion within six weeks~* currently pregnant~* currently breast-feeding~* undiagnosed abnormal uterine bleeding pre-dating placement of contraceptive implant~* bleeding dyscrasia~* anticoagulation use~* active cervicitis~* allergy to tamoxifen~* history of venous thromboembolism~* current or past breast or uterine malignancy~* use of medication contraindicated with tamoxifen (coumadin, letrozole, bromocriptine, rifampicin, aminoglutethimide, phenobarbital).

- Gender: FEMALE
- Minimum Age: 15 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Tamoxifen (Type: EXPERIMENTAL): Tamoxifen 10 mg (oral) twice daily for 7 days to be started following 3 consecutive days of bleeding
- Placebo (Type: PLACEBO_COMPARATOR): Placebo (oral) twice daily for 7 days to be started following 3 consecutive days of bleeding

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: RehabTouch Home Therapy for Stroke Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age: 18 to 85 years old~* Upper extremity weakness measured by a clinical scale~* Absence of moderate to severe pain on affected upper extremity~* Able to understand the instructions to operate RehabTouch~Exclusion Criteria:~* Concurrent severe medical problems, visual deficits, severe neglect or apraxia~* Enrollment to other therapy studies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- RehabTouch Exercise Program (Type: EXPERIMENTAL): Participants will perform targetted movement exercises by interacting with the RehabTouch pucks, as described and monitored on a computer. Participants will be asked to exercise at least 3 hours per week for 3 consecutive weeks.
- Conventional tabletop exercise program (Type: ACTIVE_COMPARATOR): Conventional tabletop exercise program is a traditional exercise program described in a booklet similar to what is typical provided to stroke patients upon their discharge from the hospital. Participants will be asked to perform these exercises at least 3 hours per week for 3 consecutive weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, and Pharmacokinetic Study of TRK-250 for Patients With Idiopathic Pulmonary Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical, radiographic, and histologic features consistent with the diagnosis of IPF~* SpO2 ≥90% at rest by pulse oximetry while breathing ambient air.~* FVC ≥50% of predicted.~* FEV1 ≥50% of predicted.~* Ratio of FEV1 to FVC ≥0.7.~* DLCO corrected for hemoglobin 30% to 79% of predicted, inclusive.~Exclusion Criteria:~* History of acute exacerbation of IPF or respiratory tract infection within 3 months prior to Screening.~* Planned surgery during the study.~* History of malignant tumor within 5 years prior to Screening.~* History of emphysema or clinically significant respiratory diseases (other than IPF).~* Other known causes of interstitial lung disease (eg, drug toxicities, environmental exposures, connective tissue diseases).~* End-stage fibrotic disease expected to require organ transplantation within 6 months.~* Taking a systemic corticosteroid, cytotoxic therapy, vasodilator therapy for pulmonary hypertension, or unapproved treatment for IPF within 4 weeks prior to Screening. (Treatment with pirfenidone or nintedanib, though not both concurrently, is permitted, provided that the subject has been on a stable dose for at least 4 weeks prior to Screening and it is anticipated the dose will remain unchanged throughout enrollment.)

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- TRK-250 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete